Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma-Reference-Cited by-同舟云学术

Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma

Published:2015-12 Issue:3 Volume:90 Page:457-464
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Santarelli Lory,Staffolani Sara,Strafella Elisabetta,Nocchi Linda,Manzella Nicola,Grossi Paola,Bracci Massimo,Pignotti Elettra,Alleva Renata,Borghi Battista,Pompili Cecilia,Sabbatini Armando,Rubini Corrado,Zuccatosta Lina,Bichisecchi Elisabetta,Valentino Matteo,Horwood Keith,Comar Manola,Bovenzi Massimo,Dong Lan-Feng,Neuzil Jiri,Amati Monica,Tomasetti Marco

Funder

National Institute against Occupational Injury Insurance

Cancer Council Queensland, National Health and Medical Research Council of Australia

Czech Science Foundation

Griffith University Senior Research Fellowship

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference45 articles.

1. The case for a global ban on asbestos;LaDou;Environ. Health Perspect.,2010

2. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J. Clin. Oncol.,2003